Theravance Biopharma (TBPH) Tax Provisions (2014 - 2026)
Theravance Biopharma (TBPH) reported Tax Provisions of -$1.5 million for Q1 2026, down 168.34% year-over-year from $2.2 million in Q1 2025, and down 106.36% quarter-over-quarter from $23.6 million in Q4 2025.
Theravance Biopharma (TBPH) Tax Provisions (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Tax Provisions data on file, last reported at -$1.5 million in Q1 2026.
- Tax Provisions for Q1 2026 came in at -$1.5 million, down 168.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.9 million (up 93.34% YoY), and the FY2025 annual result was $34.9 million, up 79.96% from the prior year.
- Tax Provisions declined to -$1.5 million in Q1 2026 per TBPH's latest filing, from $23.6 million in the prior quarter.
- Over five years, Tax Provisions peaked at $23.6 million in Q4 2025 and troughed at -$6.5 million in Q3 2025.
- A 5-year average of $3.5 million and a median of $1.3 million in 2024 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions slumped 7142.86% in 2022, then jumped 115766.67% in 2023.
- A 5-year view of Tax Provisions shows it stood at -$3000.0 in 2022, then jumped by 115766.67% to $3.5 million in 2023, then surged by 308.1% to $14.2 million in 2024, then soared by 66.45% to $23.6 million in 2025, then tumbled by 106.36% to -$1.5 million in 2026.
- Business Quant data shows TBPH's Tax Provisions at -$1.5 million in Q1 2026, $23.6 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 216,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.50 Mn |
| Dec 31, 2025 | 23.57 Mn |
| Sep 30, 2025 | -6.50 Mn |
| Jun 30, 2025 | 18.37 Mn |
| Mar 31, 2025 | -559,000.00 |
| Dec 31, 2024 | 14.16 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.46 Mn |
| Mar 31, 2023 | -395,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -507,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 524,000.00 |
| Dec 31, 2021 | -151,000.00 |
| Sep 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -220,000.00 |